1401517-91-6

Basic information

• Product Name: N-(2-phenylethyl)indole-5-carboxamide
• Synonyms: N-(2-phenylethyl)indole-5-carboxamide
• CAS NO: 1401517-91-6
• Molecular Weight: 264.327
• Mol File: 1401517-91-6.mol

Chemical Properties

• CAS DataBase Reference: N-(2-phenylethyl)indole-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-phenylethyl)indole-5-carboxamide(1401517-91-6)
• EPA Substance Registry System: N-(2-phenylethyl)indole-5-carboxamide(1401517-91-6)

Safety Data

• Hazardous Substances Data: 1401517-91-6(Hazardous Substances Data)

Upstream product

• 1670-81-1 1H-Indole-5-carboxylic acid 
• 64-04-0 phenethylamine 

Relevant articles and documents

The Broad Aryl Acid Specificity of the Amide Bond Synthetase McbA Suggests Potential for the Biocatalytic Synthesis of Amides

Amide bond formation is one of the most important reactions in pharmaceutical synthetic chemistry. The development of sustainable methods for amide bond formation, including those that are catalyzed by enzymes, is therefore of significant interest. The ATP-dependent amide bond synthetase (ABS) enzyme McbA, from Marinactinospora thermotolerans, catalyzes the formation of amides as part of the biosynthetic pathway towards the marinacarboline secondary metabolites. The reaction proceeds via an adenylate intermediate, with both adenylation and amidation steps catalyzed within one active site. In this study, McbA was applied to the synthesis of pharmaceutical-type amides from a range of aryl carboxylic acids with partner amines provided at 1–5 molar equivalents. The structure of McbA revealed the structural determinants of aryl acid substrate tolerance and differences in conformation associated with the two half reactions catalyzed. The catalytic performance of McbA, coupled with the structure, suggest that this and other ABS enzymes may be engineered for applications in the sustainable synthesis of pharmaceutically relevant (chiral) amides.

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).

NOVEL RHO KINASE INHIBITORS AND METHODS OF USE

The subject invention concerns materials and methods for treating diseases and disorders associated with expression of Rho associated kinases (ROCKs). Examples of diseases and disorders contemplated within the scope of the invention include, but are not limited to, oncological disorders, cardiovascular diseases, CNS disorders, and inflammatory disorders. In one embodiment, a method of the invention comprises administering a therapeutically effective amount of one or more compounds of the present invention, or a composition comprising the compounds, to a person or animal in need of treatment. The subject invention also concerns compounds that inhibit ROCKs, and compositions that comprise the inhibitor compounds of the invention. Compounds contemplated within the scope of the invention include, but are not limited to, those compounds shown in Table (5).